Li 2009

1 Treatments

Studied treatment  Nateglinide

Control treatment  repaglinide

Concomittant treatments  -

2 Patients

Patients  -

Inclusion criteria  -

Exclusion criteria  -

3 Methods

Blinding  -

Design  -

Centers  -

Geographical area  -

Sizes  9/-9

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
</table>

5 References